Praexisio Taiwan Inc. implements the concept of precision medicine, focusing on the development of personalized drug design technology that combines AI assistance and protein molecular dynamics simulation to optimize the disease-inhibiting efficacy of new drugs, thereby solving the problem of new drugs struggling to pass clinical trials due to insufficient specificity.
With the vision of becoming the most high-quality and professional integrated bioinformatics consulting service company, we provide our clients with precise and effective problem analysis and solutions. Since its co-founding in 2020 by Professor Li-Wei Yang of National Tsing Hua University, Professor Jui-Hung Hung of National Chiao Tung University, and Chairman Hsiao-San Wu of Samwell Testing Technology, the team has gathered top international scholars and cross-disciplinary engineers. We have collaborated with first-class academic research institutions and medical centers both domestically and internationally, including the University of Texas Southwestern Medical Center, National Tsing Hua University, Taipei Medical University, and National Taiwan University Hospital, and were recognized with the 19th National Innovation Award in 2022.
In addition to leveraging cutting-edge bioinformatics technology to increase the success rate of drug R&D and reduce costs, we are simultaneously developing an automated pathogenic gene interpretation system built on next-generation sequencing to improve the accuracy of complex disease diagnosis and plan precise medication treatment strategies for patients. Furthermore, to optimize work efficiency and ensure research quality, Praexisio Taiwan Inc. has developed a high-performance computing scheduling management system as well as article similarity comparison software that protects user privacy. We always uphold the principles of rigorous scientific literacy and the protection of originality, integrating invested resources to help our clients generate maximum benefits.